We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+9.78%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.3B
AUM Growth
-$82M
(-0.98%)
Cap. Flow
-$615M
Cap. Flow
% of AUM
-7.41%
Top 10 Holdings %
Top 10 Hldgs %
34.19%
Holding
170
New
23
Increased
24
Reduced
50
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$104M |
| 2 |
Cigna
CI
|
+$77.7M |
| 3 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$73.5M |
| 4 |
Molina Healthcare
MOH
|
+$62.4M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$56.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$125M |
| 2 |
Biogen
BIIB
|
+$88.7M |
| 3 |
SEM
Select Medical
SEM
|
+$77.6M |
| 4 |
Merck
MRK
|
+$75.8M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$74.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.81% |
| 2 | Financials | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Coherus Oncology
CHRS
$222M
| $28.4M | 0.34% |
1,722,400
+241,918
| +16% | +$4.29M |
|
77
Gilead Sciences
GILD
$167B
| $28.2M | 0.34% |
364,600
| – | – |
|
78
Cartesian Therapeutics
RNAC
$225M
| $26.3M | 0.32% |
56,427
-5,000
| -8% | -$2.01M |
|
79
Verrica Pharmaceuticals
VRCA
$92.8M
| $24M | 0.29% |
147,973
| – | – |
|
80
Stryker
SYK
$133B
| $23.1M | 0.28% |
130,200
-13,200
| -9% | -$2.25M |
|
81
CRISPR Therapeutics
CRSP
$4.68B
| $22M | 0.27% |
496,200
| – | – |
|
|
SVA
82
DELISTED
Sinovac Biotech, Ltd
SVA
| $21.6M | 0.26% |
2,839,500
| – | – |
|
|
NVTA
83
DELISTED
Invitae Corporation
NVTA
| $21.3M | 0.26% |
1,274,549
-243,648
| -16% | -$2.77M |
|
|
FOLD
84
DELISTED
Amicus Therapeutics
FOLD
| $21.3M | 0.26% |
1,763,277
-5,309,223
| -75% | -$74.2M |
|
85
Intellia Therapeutics
NTLA
$1.52B
| $21.3M | 0.26% |
744,600
-131,400
| -15% | -$3.82M |
|
|
ALPN
86
DELISTED
Alpine Immune Sciences Inc
ALPN
| $20.9M | 0.25% |
3,298,516
| – | – |
|
87
Spyre Therapeutics
SYRE
$8.68B
| $20.7M | 0.25% |
86,621
+12,000
| +16% | +$2.8M |
|
|
SCPH
88
DELISTED
scPharmaceuticals
SCPH
| $20M | 0.24% |
3,409,865
| – | – |
|
|
AET
89
DELISTED
Aetna Inc
AET
| $19.9M | 0.24% |
+98,200
| New | +$19.2M |
|
90
CALL
Vertex Pharmaceuticals
VRTX
$124B
| $19.3M | 0.23% |
100,000
-75,000
| -43% | -$13.4M |
|
91
Rocket Pharmaceuticals
RCKT
$343M
| $19.1M | 0.23% |
775,000
| – | – |
|
|
SEM
92
DELISTED
Select Medical
SEM
| $19M | 0.23% |
1,920,424
-7,497,291
| -80% | -$77.6M |
|
93
Neurocrine Biosciences
NBIX
$18.4B
| $16.9M | 0.2% |
137,800
| – | – |
|
94
Natera
NTRA
$36.1B
| $16.4M | 0.2% |
684,086
-300,000
| -30% | -$7.25M |
|
|
WHWK
95
Whitehawk Therapeutics
WHWK
$182M
| $16M | 0.19% |
346,263
| – | – |
|
|
VRNA
96
DELISTED
Verona Pharma
VRNA
| $15.6M | 0.19% |
1,250,396
| – | – |
|
|
NVO
97
Novo Nordisk
NVO
$225B
| $15.6M | 0.19% |
660,000
| – | – |
|
|
DBVT
98
DBV Technologies
DBVT
$799M
| $14.9M | 0.18% |
66,520
+25,450
| +62% | +$5.17M |
|
|
IMGN
99
DELISTED
Immunogen Inc
IMGN
| $13.9M | 0.17% |
1,469,189
-1,435,081
| -49% | -$13.8M |
|
|
PVLA
100
Palvella Therapeutics
PVLA
$2.05B
| $13.8M | 0.17% |
30,699
-8,551
| -22% | -$3.72M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q3 2018 Portfolio in Review
As of Q3 2018, OrbiMed held 170 positions worth $8.3B, down 0.98% from $8.38B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed withdrew a net $615M in Q3 2018, closing 20 positions and reducing 50 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $125M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials.
Against the trend, OrbiMed opened a new position in Principia Biopharma Inc. Common Stock worth $76.1M.
- OrbiMed's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,605,713 shares worth $76.1M.
- OrbiMed added most to Humana in Q3 2018, an estimated $104M increase.
- OrbiMed's biggest Q3 2018 reduction was Biogen, cutting an estimated $88.7M.
- OrbiMed fully exited Alnylam Pharmaceuticals in Q3 2018, selling an estimated $125M.
- OrbiMed's ten largest holdings make up 34% of its $8.3B portfolio in Q3 2018.
- OrbiMed opened 23 new positions and closed 20 in Q3 2018.
- OrbiMed's portfolio value fell 0.98% quarter-over-quarter to $8.3B.
Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.